Abstract:Copeptin is a 39-amino-acid long glycosylated peptide with a leucine-rich core segment in the C-terminal part of pre-pro-vasopressin. It exhibits a rapid response comparable to arginine vasopressin (AVP) in response to osmotic, hemodynamic, and nonspecific stress-related stimuli. This similarity can be attributed to equimolar production of copeptin alongside AVP. However, there are markedly different decay kinetics for both peptides, with an estimated initial half-life of copeptin being approximately two times longer than that of AVP. Like AVP, copeptin correlates strongly over a wide osmolality range in healthy individuals, making it a useful alternative to AVP measurement. While copeptin does not appear to be significantly affected by food intake, small amounts of oral fluid intake may result in a significant decrease in copeptin levels. Compared to AVP, copeptin is considerably more stable in vitro. An automated immunofluorescent assay is now available and has been used in recent landmark trials. However, separate validation studies are required before copeptin thresholds from these studies are applied to other assays. The biological variation of copeptin in presumably healthy subjects has been recently reported, which could assist in defining analytical performance specifications for this measurand. An established diagnostic utility of copeptin is in the investigation of polyuria-polydipsia syndrome and copeptin-based testing protocols have been explored in recent years. A single baseline plasma copeptin >21.4 pmol/L differentiates AVP resistance (formerly known as nephrogenic diabetes insipidus) from other causes with 100% sensitivity and specificity, rendering water deprivation testing unnecessary in such cases. In a recent study among adult patients with polyuria-polydipsia syndrome, AVP deficiency (formerly known as central diabetes insipidus) was more accurately diagnosed with hypertonic saline-stimulated copeptin than with arginine-stimulated copeptin. Glucagon-stimulated copeptin has been proposed as a potentially safe and precise test in the investigation of polyuria-polydipsia syndrome. Furthermore, copeptin could reliably identify those with AVP deficiency among patients with severe hypernatremia, though its diagnostic utility is reportedly limited in the differential diagnosis of profound hyponatremia. Copeptin measurement may be a useful tool for early goal-directed management of post-operative AVP deficiency. Additionally, the potential prognostic utility of copeptin has been explored in other diseases. There is an interest in examining the role of the AVP system (with copeptin as a marker) in the pathogenesis of insulin resistance and diabetes mellitus. Copeptin has been found to be independently associated with an increased risk of incident stroke and cardiovascular disease mortality in men with diabetes mellitus. Increased levels of copeptin have been reported to be independently predictive of a decline in estimated glomerular filtration rate and a greater risk of new-onset chronic kidney disease. Furthermore, copeptin is associated with disease severity in patients with autosomal dominant polycystic kidney disease. Copeptin predicts the development of coronary artery disease and cardiovascular mortality in the older population. Moreover, the predictive value of copeptin was found to be comparable with that of N-terminal pro-brain natriuretic peptide for all-cause mortality in patients with heart failure. Whether the measurement of copeptin in these conditions alters clinical management remains to be demonstrated in future studies.

Oral Levodopa Stimulates Copeptin Secretion in Children and Adolescents with Intact Posterior Pituitary Function

Arginine-stimulated copeptin in children and adolescents

Evaluation of copeptin in children after stimulation with clonidine or L-Dopa

Insulin-Induced Copeptin Response in Children and Adolescents to Diagnose Arginine Vasopressin Deficiency

Very elevated serum copeptin concentrations occur in a subset of healthy children in the minutes after phlebotomy

Surrogate Markers and Predictors of Endogenous Insulin Secretion in Children and Adolescents with Type 1 Diabetes

Copeptin as a surrogate marker for arginine vasopressin: analytical insights, current utility, and emerging applications

L-DOPA Test in the Diagnosis of Childhood Short Stature: Evaluation of Growth Hormone Peaks Over Time

The diagnostic performance of copeptin in clinical practice: A prospective study

Copeptin as a diagnostic and prognostic biomarker in pediatric diseases

Copeptin analysis in endocrine disorders

A-072 Growth hormone stimulation tests: experience of a large cohort from a Brazilian diagnostic medical center

Paediatric perspectives in the diagnosis of polyuria‐polydipsia syndrome

Metabolomic Differential Compounds Reflecting the Clinical Efficacy of Polyethylene Glycol Recombinant Human Growth Hormone in the Treatment of Childhood Growth Hormone Deficiency

Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children.

Copeptin is Significantly Elevated in Obese Children and Closely Related to Insulin Resistance

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine

Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study

[Diagnostic Value of the Propranolol-Exercise Provocative Test for Growth Hormone Deficiency in Children].

Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests

Copeptin as a potential biomarker of chronic kidney disease to predict the disease progression in children with chronic kidney disease